Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects

NCT06180720 | Unknown Phase 1

• 1 other identifier: QLG1114-02
• Study Type: interventional
• Target: 36
• Locations: 0 countries
• Sites: N/A

Brief Summary

In this trial, 36 healthy subjects are planned to be enrolled in postprandial, and the postprandial trials will be randomized separately. According to the randomization table, subjects will be randomly assigned to one of the two groups (Group A: TRTR, Group B: RTRT). The washout period (dosing interval) between doses will be at least 2 days. Taking the washout period of 2 days as an example, all subjects will take the corresponding medication according to the randomization table on day 1 of the first cycle trial, day 3 of the second cycle trial, day 5 of the third cycle trial, and day 7 of the fourth cycle trial.

Conditions

Healthy

Outcome Measures

Primary Outcomes (3)

• Peak Plasma Concentration (Cmax)

  Evaluation of Peak Plasma Concentration (Cmax)

  10hours

• Area under the plasma concentration versus time curve (AUC0-t)

  Area under the drug concentration-time curve from time 0 to the last accurately measurable concentration at sample collection time t

  10hours

• Area under the plasma concentration versus time curve (AUC0-∞)

  Area Under the Plasma Drug Concentration-Time Curve from Time 0 to Infinite Time

  10hours

Study Arms (2)

Test (T)-Reference (R)

EXPERIMENTAL

In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group A: Test (T)-Reference (R), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.

Drug: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II); Drug: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)

Reference (R)-Test (T)

EXPERIMENTAL

In this trial, 36 healthy subjects are planned to be enrolled in fasting. According to the randomization table, subjects will be randomly assigned to the Group B: Reference (R)-Test (T), The washout period (dosing interval) between doses will be at least 2 days. After fasting for at least 10 hours.

Drug: Test (T) Entacapone,Levodopa and Carbidopa Tablets (II); Drug: Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II)

Interventions

Test (T) Entacapone,Levodopa and Carbidopa Tablets (II) DRUG

Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Produced and supplied by Qilu Pharmaceutical Co.

Reference (R)-Test (T); Test (T)-Reference (R)

Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) DRUG

Specification:Levodopa 100mg, Carbidopa 25mg, Entacapone 200mg(Abbreviation: 100mg/25mg/200mg). Supplied by Qilu Pharmaceutical Co.

Reference (R)-Test (T); Test (T)-Reference (R)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign an informed consent form before the trial and fully understand the content, process and possible adverse effects of the trial.
• Ability to complete research in accordance with the requirements of the pilot program.
• The subject is willing to be free of pregnancy, sperm or egg donation and to voluntarily use effective contraception from the time of signing (female subject has used effective contraception for 14 days prior to the first dose of the drug) to 6 months after the last dose of the drug.
• Healthy male and female subjects aged 18 years or older (including 18 years of age).
• Male subjects weighed no less than 50.0 kg and female subjects weighed no less than 45.0 kg, with a body mass index in the range of 19.0 to 28.0 kg/m2 (including threshold values).

You may not qualify if:

• History of serious medical conditions such as cardiac, hepatic, renal, gastrointestinal, neurological, endocrine, respiratory, and psychiatric abnormalities, which are deemed inappropriate for the participant by the study physician#
• Abnormalities judged by the clinician to be clinically significant, including physical examination, vital signs examination, electrocardiogram, or clinical laboratory tests#
• Previous or existing postural hypotension or morning dizziness#
• Those with bile duct obstruction or a history of bile duct obstruction, or those with narrow-angle glaucoma, chronic open-angle glaucoma, ischemic heart disease, or myocardial infarction disease or history#
• Previous or existing suspicious and undiagnosed skin lesions or a history of melanoma#
• Those with a history of malignant nerve blocker syndrome (NMS) and/or non-traumatic rhabdomyolysis#
• Persons with a history of specific allergies (asthma, etc.) or current allergic diseases (hives, eczema, etc.), or allergies (e.g., persons allergic to two or more medications, foods such as milk, or pollen), or known allergies to carbidopa, levodopa, entacapone, or any of the drug components#
• Those with dysphagia or any history of gastrointestinal disorders that interfere with drug absorption (e.g., gastric or small bowel resection, atrophic gastritis, peptic ulcer, gastrointestinal bleeding, obstruction, etc.)#
• Female subjects who are pregnant, breastfeeding, or have a positive pregnancy test result
• Those who are positive for any one or more of Hepatitis B Surface Antigen, Hepatitis C Antibody, HIV Antibody, or Syphilis Antibody#
• History of substance abuse within five years, or drug use within three months prior to screening, or positive urine drug screen#
• Those who consumed an average of more than 14 units of alcohol (1 unit = 360 milliliter of beer or 45 milliliter of spirits with 40% alcohol by volume or 150 milliliter of wine) per week in the 3 months prior to screening, or those who were unable to stop their alcohol intake from 24h prior to dosing until the end of the trial, or those who had a positive breath test for alcohol#
• Those who smoked an average of more than 5 cigarettes per day in the 3 months prior to screening or those who refused not to use tobacco products during their stay#
• History of surgical procedure within 3 months prior to screening or planned surgery during the study period#
• Those who have donated blood or lost a significant amount of blood (\>400milliliter, except for physiologic blood loss in females) within 3 months prior to the first dose, or those who have donated ≥2 therapeutic doses of platelets within 1 month#

Sponsors & Collaborators

• The Affiliated Hospital of Qingdao University: lead

MeSH Terms

Interventions

entacapone; Levodopa; Carbidopa

Intervention Hierarchy (Ancestors)

Dihydroxyphenylalanine; Catecholamines; Amines; Organic Chemicals; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenylalanine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Tyrosine; Methyldopa; Hydrazines

Study Officials

• Yu Cao

  The Affiliated Hospital of Qingdao University Phase I Clinical Research Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yu Cao

CONTACT

18661809090; caoyu1767@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Clinical Trials Center of Affiliated Hospital of Qingdao Universit

Study Record Dates

• First Submitted: December 13, 2023
• First Posted: December 22, 2023
• Study Start: December 20, 2023
• Primary Completion: January 4, 2024
• Study Completion: November 20, 2024
• Last Updated: December 22, 2023

Record last verified: 2023-12